Tech Company Financing Transactions

HEPHAISTOS-Pharma Funding Round

HEPHAISTOS-Pharma, based in Orsay, secured $2.2 million in investment from Xista Science Ventures and Noshaq.

Transaction Overview

Company Name
Announced On
1/24/2024
Transaction Type
Venture Equity
Amount
$2,170,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to finance GMP transfer and advance its lead candidate towards the clinic. The proceeds from this financing round will enable HEPHAISTOS to industrialize its manufacturing process and prepare for the clinical phases, with the goal of advancing its lead candidate, ONCO-Boost, into clinical development for the treatment of solid tumors with high unmet medical needs, in particular sarcoma. The proceeds will also be used to open a new subsidiary in Liège, Wallonia.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2 Rue Jean Rostand
Orsay, 91400
France
Phone
Undisclosed
Email Address
Not Recorded
Overview
A preclinical stage Biotech company developing the next generation of oncology treatments that will be boost immune system to treat incurable cancers. Immunotherapy has shown impressive results in the past 5 years by treating cancers like never seen before. Unfortunately, success levels are still very low and only 10% of patients can be cured today.
Profile
HEPHAISTOS-Pharma LinkedIn Company Profile
Social Media
HEPHAISTOS-Pharma Company Twitter Account
Company News
HEPHAISTOS-Pharma News
Facebook
HEPHAISTOS-Pharma on Facebook
YouTube
HEPHAISTOS-Pharma on YouTube

Management Team

Title
Name
Email & Social
Chairman
Martine Caroff
  Martine Caroff LinkedIn Profile  Martine Caroff Twitter Account  Martine Caroff News  Martine Caroff on Facebook
Chief Executive Officer
Frederic Caroff
  Frederic Caroff LinkedIn Profile  Frederic Caroff Twitter Account  Frederic Caroff News  Frederic Caroff on Facebook


 

 

Browse more venture capital transactions:

Prev: 1/24/2024: CryptoSafe venture capital transaction
Next: 1/24/2024: Circular Genomics venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on tech company VC transactions. VC investment data records reported here are derived from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary